Intravenous Iron Versus Erythropoiesis-Stimulating Agents: Friends or Foes in Treating Chronic Kidney Disease Anemia?

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 143-151

  Kalantar Zadeh, Kamyar ^a   Streja, Elani ^a   Miller, Jessica E ^a   Nissenson, Allen R ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Erythropoiesis stimulating agent; Ferritin; Inflammation; Intravenous iron; Transferrin saturation ratio

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON; TRANSFERRIN;

ANEMIA; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; DEATH; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFLAMMATION; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON DEPLETION; IRON THERAPY; LIVER DISEASE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; RISK; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ANEMIA, IRON-DEFICIENCY; FERRITINS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; TRANSFERRIN; TREATMENT OUTCOME;

EID: 60349120822     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.12.008     Document Type: Article

References (57)

1. Eschbach J.W., Kelly M.R., Haley N.R., et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321 (1989) 158-163
2. Singh A.K. Anemia of chronic kidney disease. Clin J Am Soc Nephrol 3 (2008) 3-6
3. Steinbrook R. Medicare and erythropoietin. N Engl J Med 356 (2007) 4-6
4. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
5. Eschbach J.W. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 18 (2005) 347-361
6. Kalantar-Zadeh K., Kalantar-Zadeh K., and Lee G.H. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Neph 1 Suppl (2006) S9-S18
7. Fernandez-Rodriguez A.M., Guindeo-Casasus M.C., Molero-Labarta T., et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 34 (1999) 508-513
8. Kalantar-Zadeh K., Hoffken B., Wunsch H., et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995) 292-299
9. Fishbane S., Shapiro W., Dutka P., et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 (2001) 2406-2411
10. Asanuma M., Taguchi C., Uesaka H., et al. Discrepancy between the percentage of hypochromic erythrocytes and the reticulocyte hemoglobin content in hemodialysis patients with recombinant human erythropoietin therapy. Lab Hematol 11 (2005) 124-130
11. Chiang W.C., Tsai T.J., Chen Y.M., et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58 (2002) 363-369
12. Canavese C., Grill A., Decostanzi E., et al. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients. Clin Nephrol 53 (2000) 42-47
13. Malyszko J., Malyszko J.S., Hryszko T., et al. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?. Am J Nephrol 25 (2005) 586-590
14. Harrison P.M., and Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275 (1996) 161-203
15. Macdougall I.C., Cavill I., Hulme B., et al. Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304 (1992) 225-226
16. Kawabata H., Tomosugi N., Kanda J., et al. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92 (2007) 857-858
17. Rambod M., Kovesdy C.P., and Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 3 (2008) 1691-1701
18. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
19. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
20. Kalantar-Zadeh K., Kleiner M., Dunne E., et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31 (1998) 263-272
21. Bross R., Zitterkoph J., Pithia J., et al. Association of serum total iron binding capacity measured transferrin and its changes with inflammation, nutrition, quality of life, and survival in maintenance hemodialysis patients. Am J Nephrol (2009) (in press)
22. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43 (2004) 671-684
23. National Kidney Foundation I, Kidney-Dialysis Outcome Quality Initiative. K/DOQI Clinical Practice Guidelines: Anemia of Chronic Kidney Disease. Am J Kidney Dis 37 Suppl 1 (2001) S182-S238
24. Kalantar-Zadeh K., and Luft F.C. Diagnosis of iron deficiency in ESRD patients. Am J Kidney Dis 30 (1997) 455-456
25. Neyra N.R., Hakim R.M., Shyr Y., et al. Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. J Ren Nutr 10 (2000) 184-190
26. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
27. Kopelman R.C., Smith L., Peoples L., et al. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int 11 (2007) 238-246
28. Fishbane S., Kalantar-Zadeh K., and Nissenson A.R. Serum ferritin in chronic kidney disease: Reconsidering the upper limit for iron treatment. Semin Dial 17 (2004) 336-341
29. Kalantar-Zadeh K., Rodriguez R.A., and Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 141-149
30. Eleftheriadis T., Kartsios C., Liakopoulos V., et al. Does hepcidin affect erythropoiesis in hemodialysis patients?. Acta Haematol 116 (2006) 238-244
31. Kalantar-Zadeh K., Don B.R., Rodriguez R.A., et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37 (2001) 564-572
32. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
33. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
34. Parfrey P.S., Foley R.N., Wittreich B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
35. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
36. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
37. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
38. Phrommintikul A., Haas S.J., Elsik M., et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
39. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736
40. Johnson D.W., Pollock C.A., and Macdougall I.C. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 12 (2007) 321-330
41. Kalantar-Zadeh K., and Aronoff G.R. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Neph (2009) (in press)
42. Berger K., von Eckardstein A., Trenkwalder C., et al. Iron metabolism and the risk of restless legs syndrome in an elderly general population-The MEMO-Study. J Neurol 249 (2002) 1195-1199
43. Collado-Seidel V., Kohnen R., Samtleben W., et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 31 (1998) 324-328
44. Murray M.J., Murray A.B., Murray M.B., et al. The adverse effect of iron repletion on the course of certain infections. Br Med J 2 (1978) 1113-1115
45. Bregman H., and Gelfand M.C. Iron overload in patients on maintenance hemodialysis. Int J Artif Organs 4 (1981) 56-57
46. Waterlot Y., Cantinieaux B., Hariga-Muller C., et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J 291 (1985) 501-504 Clin Res Ed
47. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65 (2004) 2108-2112
48. Zager R.A., Johnson A.C., Hanson S.Y., et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
49. Seifert A., von Herrath D., and Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65 (1987) 1015-1024
50. Drueke T., Witko-Sarsat V., Massy Z., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (2002) 2212-2217
51. Feldman H.I., Santanna J., Guo W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002) 734-744
52. Salonen J.T., Nyyssonen K., Korpela H., et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86 (1992) 803-811
53. Sempos C.T. Do body iron stores increase the risk of developing coronary heart disease?. Am J Clin Nutr 76 (2002) 501-503
54. Sempos C.T., Looker A.C., Gillum R.F., et al. Body iron stores and the risk of coronary heart disease. N Engl J Med 330 (1994) 1119-1124
55. Weiss G., Meusburger E., Radacher G., et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64 (2003) 572-578
56. Feldman H.I., Joffe M., Robinson B., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15 (2004) 1623-1632
57. National Kidney Foundation I. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kid Dis 47 Suppl (2006) 146-146